4.7 (13)
Two global Phase 3 clinical trials testing the investigational oral medication evobrutinib are recruiting participants with relapsing forms of multiple sclerosis (MS).
The two identically-designed trials EVOLUTION RMS 1 (NCT04338022) and EVOLUTION RMS 2 (NCT04338061) are specifically recruiting people with MS ages 18 to 55.
The trials are recruiting at locations around the world. A full list of U.S. locations for both trials is available at the National Multiple Sclerosis Society website; full location lists and contact details are available at the respective links.
Participants in the studies will need to make in-person visits to study sites. Precautions are being taken to help keep participants safe during in-person visits in the context of the COVID-19 pandemic.